MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

A real-world, retrospective study demonstrates that clinical next-generation sequencing panels provide significant prognostic and predictive data in mantle cell lymphoma, aiding in the optimization of patient management.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

This Chinese real-world study characterizes the clinical features and poor prognosis of blastoid/pleomorphic MCL, providing data to help risk-stratify and manage this aggressive subtype.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

This large epidemiological study identifies mantle cell lymphoma as one of the most frequent and aggressive nodal non-Hodgkin lymphoma subtypes in North Africa, highlighting regional disease patterns.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

This US real-world study describes treatment patterns and outcomes for covalent BTK inhibitors in relapsed/refractory MCL, providing crucial benchmarks for routine clinical practice outside of trial settings.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.

Real-world data from an Italian compassionate use program confirms pirtobrutinib's efficacy in heavily pre-treated, relapsed/refractory MCL, including patients who have failed prior covalent BTK inhibitors.

In a real-world French cohort, MCL patients failing CAR-T therapy have dismal outcomes (median OS 5.8 months), highlighting an urgent need for effective salvage, with bispecific antibodies showing promise.

A matching-adjusted indirect comparison suggests pirtobrutinib improves survival versus standard of care for relapsed/refractory MCL patients who have progressed on a prior covalent BTKi, supporting its use.

This multi-center study provides real-world data on treatment outcomes for elderly mantle cell lymphoma patients, offering crucial insights for managing this common and clinically challenging population.

This real-world Colombian cohort confirms MIPI score as a key prognostic factor in MCL, where age-stratified frontline chemotherapy resulted in comparable responses despite different treatment intensities.

Prophylactic siltuximab, guided by rising CRP, effectively managed cytokine release syndrome from bispecifics while minimizing infections by avoiding corticosteroids, a promising toxicity management strategy for MCL patients.

In a large low-grade lymphoma cohort, MCL histology was a key risk factor for lymphoma-related death, while secondary malignancies drove non-lymphoma mortality, underscoring diverse survival threats.

This real-world database analysis shows MCL patients treated at academic centers had significantly longer overall survival and higher trial participation, highlighting a major care disparity versus community settings.

Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.